AppLovin (APP) surged to new all-time highs Monday, gaining 12% and adding roughly $14 billion to its market capitalization, as it officially joined the S & P 500 Index. The breakout through final resistance is a bullish technical development, acting as a positive catalyst and clearing the chart of overhead supply. Breakouts are most reliable when sustained for a few days. For APP, we would like to see the stock price hold above the prior resistance level of $525 into next week to reduce the risk of a buying climax. This would validate the breakout. With the stock at new all-time highs, there is no resistance to reference as an upside objective. Instead, we can assume the trajectory of the uptrend will maintain itself and assign a “measured move” projecting the first leg of an uptrend from a corrective low. This suggests APP has the potential to reach $663 over the long term. Momentum had already been strengthening ahead of today’s announcement. The weekly MACD registered a bullish crossover in early August following a constructive higher low, and the monthly MACD histogram continues to expand, pointing to sustained long-term strength. While the stochastic oscillator is overbought, as long as its reading remains above 80%, the bullish signals from MACD take precedence. Should APP hold onto its gains after today’s breakout, former resistance of $525 becomes a gauge of initial support on the chart. The news-driven gap also has the potential to frame support, for which we would reference today’s intraday low. It would be encouraging to see the stock hold above both levels in the near term. APP is a member of the technology sector, and like the sector, it has shown its ability to exhibit leadership on the upside and downside. The stock’s adjusted beta is 2.5, the highest among S & P 500 constituents, followed closely by Super Micro Computer (SMCI). This reminds us to manage risk because the technical picture could deteriorate quickly if the market pivots. —Katie Stockton with Will Tamplin Access research from Fairlead Strategies for free here . DISCLOSURES: (None) All opinions expressed by the CNBC Pro contributors are solely their opinions and do not reflect the opinions of CNBC, NBC UNIVERSAL, their parent company or affiliates, and may have been previously disseminated by them on television, radio, internet or another medium. THE ABOVE CONTENT IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY . THIS CONTENT IS PROVIDED FOR INFORMATIONAL PURPOSES ONLY AND DOES NOT CONSITUTE FINANCIAL, INVESTMENT, TAX OR LEGAL ADVICE OR A RECOMMENDATION TO BUY ANY SECURITY OR OTHER FINANCIAL ASSET. THE CONTENT IS GENERAL IN NATURE AND DOES NOT REFLECT ANY INDIVIDUAL’S UNIQUE PERSONAL CIRCUMSTANCES. THE ABOVE CONTENT MIGHT NOT BE SUITABLE FOR YOUR PARTICULAR CIRCUMSTANCES. BEFORE MAKING ANY FINANCIAL DECISIONS, YOU SHOULD STRONGLY CONSIDER SEEKING ADVICE FROM YOUR OWN FINANCIAL OR INVESTMENT ADVISOR. Click here for the full disclaimer. Fairlead Strategies Disclaimer: This communication has been prepared by Fairlead Strategies LLC (“Fairlead Strategies”) for informational purposes only. This material is for illustration and discussion purposes and not intended to be, nor construed as, financial, legal, tax or investment advice. You should consult appropriate advisors concerning such matters. This material presents information through the date indicated, reflecting the author’s current expectations, and is subject to revision by the author, though the author is under no obligation to do so. This material may contain commentary on broad-based indices, market conditions, different types of securities, and cryptocurrencies, using the discipline of technical analysis, which evaluates the demand and supply based on market pricing. The views expressed herein are solely those of the author. This material should not be construed as a recommendation, or advice or an offer or solicitation with respect to the purchase or sale of any investment. The information is not intended to provide a basis on which you could make an investment decision on any particular security or its issuer. This document is intended for CNBC Pro subscribers only and is not for distribution to the general public. Certain information has been provided by and/or is based on third party sources and, although such information is believed to be reliable, no representation is made with respect to the accuracy, completeness, or timeliness of such information. This information may be subject to change without notice. Fairlead Strategies undertakes no obligation to maintain or update this material based on subsequent information and events or to provide you with any additional or supplemental information or any update to or correction of the information contained herein. Fairlead Strategies, its officers, employees, affiliates and partners shall not be liable to any person in any way whatsoever for any losses, costs, or claims for your reliance on this material. Nothing herein is, or shall be relied on as, a promise or representation as to future performance. PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS. Opinions expressed in this material may differ or be contrary to opinions expressed, or actions taken, by Fairlead Strategies or its affiliates, or their respective officers, directors, or employees. In addition, any opinions and assumptions expressed herein are made as of the date of this communication and are subject to change and/or withdrawal without notice. Fairlead Strategies or its affiliates may have positions in financial instruments mentioned, may have acquired such positions at prices no longer available, and may have interests different from or adverse to your interests or inconsistent with the advice herein. Any investments made are made under the same terms as nonaffiliated investors and do not constitute a controlling interest. No liability is accepted by Fairlead Strategies, its officers, employees, affiliates, or partners for any losses that may arise from any use of the information contained herein. Any financial instruments mentioned herein are speculative in nature and may involve risk to principal and interest. Any prices or levels shown are either historical or purely indicative. This material does not take into account the particular investment objectives or financial circumstances, objectives or needs of any specific investor, and are not intended as recommendations of particular securities, investment products, or other financial products or strategies to particular clients. Securities, investment products, other financial products or strategies discussed herein may not be suitable for all investors. The recipient of this information must make its own independent decisions regarding any securities, investment products or other financial products mentioned herein. The material should not be provided to any person in a jurisdiction where its provision or use would be contrary to local laws, rules, or regulations. This material is not to be reproduced or redistributed absent the written consent of Fairlead Strategies.
String of frozen shrimp recalls related to radioactive material may be linked to Indonesia industrial site SeafoodSource
Indonesian metal facility likely source of radioactive shrimp contamination Undercurrent News
AI startup Anthropic has agreed to pay $1.5 billion to book authors to settle a copyright suit, marking the largest payout in a U.S. copyright case to date. http://f-st.co/1YbMuv7 LinkedIn
H & N Group Frozen Shrimp Recalled For Radioactivity Food Poisoning Bulletin
Radioactive shrimp issue will not hinder export to US: Minister ANTARA News
A quality improvement intervention implemented at two urgent care centers in an integrated healthcare system was associated with increased adoption of 5-day antibiotic durations for common outpatient infections, researchers reported today in Open Forum Infectious Diseases.
The Take 5 campaign, implemented at Denver Health in December 2019, is a multifaceted antibiotic stewardship intervention to promote adherence to institutional guidance for 5-day antibiotic durations for skin infections, urinary tract infections, sinusitis (sinus infection), otitis media (earache), pneumonia, and chronic obstructive pulmonary disease (COPD) exacerbations. To assess its performance, researchers from Denver Health examined urgent care visits from January 2017 through December 2023, calculating the proportion of antibiotic prescriptions for the pre-specified infections that were 5 days or less before and after the intervention was implemented.
Over the study period, the investigators documented 32,352 visits for the pre-specified infections where an antibiotic was prescribed—14,698 before the intervention and 17,654 during the intervention. While there was a significant increasing trend in the proportion of prescriptions for 5 days or less prior to the intervention, there was an estimated 10.7% increase in prescriptions for 5 days or less immediately after the intervention started, followed by an increase of 0.18% per month over the course of the intervention.
“Therefore, the intervention had a strong immediate effect and was associated with sustained increases in five-day durations of therapy over time,” the study authors wrote.
An effective stewardship approach
The aggregate proportion of prescriptions for 5 days or less rose from 57.5% pre-intervention to 82.9% after implementation. Subgroup analysis by infection type found an immediate effect of the intervention on prescriptions for sinusitis, cellulitis or skin abscess, acute cystitis, and COPD exacerbation. Rates of new antibiotic prescriptions and hospitalizations within 14 days were similar between the periods.
The authors say the campaign resulted in 6,000 fewer antibiotic-days dispensed per year, a more than 20% decline.
“Promoting use of the shortest effective duration of therapy for infections where antibiotics are indicated or may be indicated appears to be an effective antibiotic stewardship approach in the urgent care setting and may complement efforts to prevent unnecessary antibiotic prescriptions for acute respiratory infections,” they concluded.
François Bayrou has been ousted in a confidence vote after only nine months as prime minister, collapsing his minority government and plunging France into a political crisis.
Bayrou, 74, will hand his resignation to Emmanuel Macron, his longterm centrist ally, on Tuesday morning.
The French president now faces the challenge of appointing his third prime minister in only one year, and the fifth since he began his second term of office in 2022. His office said he would make the decision “in the coming days”.
Bayrou was toppled when 364 deputies voted that they had no confidence in the government. Just 194 gave him their confidence. Bayrou had called the vote himself as a last-ditch gamble for support, saying he needed backing from parliament for austerity measures to reduce the public debt.
In a speech to parliament before the vote, Bayrou had said France was under threat from its “inexorable swamp of debt” and must find a “compromise” on a budget. He said if some “minimal” understanding and consensus was not found in the divided parliament then “government action will be destined to fail”.
When the leaders of opposition party groups, from the left to the far right, made fiercely critical speeches against him, he said: “I won’t respond to insults” and warned that the image of verbal “violence and contempt” among politicians was damaging democracy.
Marine Le Pen of the far-right National Rally’s parliamentary group told MPs that Bayrou’s departure was “the end of the agony of a phantom government”.
Le Pen, who was found guilty in March of the embezzlement of European parliamentary funds through a fake jobs scam and banned from running for office for five years, said Macron must call a parliamentary election immediately, even if it meant she could not run again for her seat in northern France. She has appealed against her conviction and an appeal trial will begin in January.
Macron, who stunned the political world by calling a snap parliament election last year which resulted in a chamber divided into three blocs – left, centre and far right – has expressed reluctance to call another vote. The far right leads the polls and a new election could result in a similar hung parliament.
French deputies – Bayrou confidence motion vote
Politicians on the left, which won the most seats in last year’s election, but fell well short of an absolute majority, have said Macron should appoint a prime minister from their camp.
During Monday’s debate, Boris Vallaud called Macron “a defeated president” who he held responsible for “impoverishing the poor, enriching the rich and turning his back on the future”.
The Socialist MP said Bayrou’s decision to call the vote was not “an act of courage, but a cop-out”.
Mathilde Panot of La France Insoumise, a leftwing party, said Bayrou had been “severely beaten”. She added: “He wanted his hour of truth; he got it.”
Panot said that as just a third of parliament had given its confidence to Bayrou, Macron’s economic policies had a minority of support and he should also resign. The president, whose term ends in 2027, has always ruled out stepping down.
As head of state with authority on foreign policy and national security, Macron directly appoints a prime minister to run domestic affairs. But since last year’s election there has been no absolute majority in the national assembly, creating a form of political deadlock and disagreement on the budget. This means there is no certainty that a new prime minister would be safe from being ousted.
skip past newsletter promotion
after newsletter promotion
France is facing a day of protest actions on Wednesday organised online by a movement called “Block Everything”, which could see roads, schools and businesses shut down. Public sector strikes are to follow.
The priority for Macron is to appoint a prime minister able to push through a budget for 2026.
Bayrou’s unpopular plan for a €44bn (£38bn) budget squeeze and austerity programme to reduce France’s public debt is now certain to be shelved, including his contested proposal to scrap two public holidays. Any new government will return to the drawing board.
Bayrou is the second PM to fall since the snap election in June last year – the rightwing Michel Barnier was ousted after just three months in December. Bayrou had become the most unpopular French prime minister since 1958, largely over his unpopular budget but also his perceived lack of government action.
His popularity had also been dented by his stance on an abuse scandal at the Bétharram private Catholic school near his home in south-west France.
Bayrou sent several of his children to the school, where his wife also taught catechism. A parliamentary report in July found Bayrou failed to act to prevent physical and sexual abuse at the school when he served as education minister between 1993 and 1997.
Bayrou was questioned by a parliamentary inquiry about whether he knew about abuse at Bétharram and covered it up. He said he had “hidden nothing”, saying his foes were leading a political campaign of “destruction” against him.
His criticisms of the parliamentary inquiry cost him support on Monday night even among his own centrists.
The northern politician Violette Spillebout, who co-chaired the parliamentary inquiry, said that despite being a fellow centrist, she abstained in the confidence vote out of anger at Bayrou’s comments on TV this weekend that the parliamentary inquiry was a “political tribune”. She said his comments were an “insult to victims”.
The Labour Court has told lawyers it is facing a “severe impact” on its operations after the Department of Public Expenditure “blocked” the reappointment of a senior official, leaving it running at one-third capacity.
Legal professionals working in employment law were told in a statement on Monday there would be “serious delays to [the Court’s] hearing of individual employment rights cases” and to the resolution of industrial relations disputes, starting this week.
“The Labour Court received communication last week indicating that the Department of Expenditure, Infrastructure, Public Service Reform and Digitalisation, have blocked the renewal of a serving deputy chair’s warrant,” the statement said.
“From this week it means that the Labour Court will be reduced to one division.
“This will have a severe impact on the functioning of the Court and result in serious delays to its hearing of individual employment rights cases [and] its industrial relations role as an independent tribunal that investigates disputes,” the statement continued.
It’s understood the senior official involved is Alan Haugh, a barrister who has served as one of the court’s deputy chairmen since 2015, and whose official warrant is due to expire at the end of this week.
The Labour Court ordinarily operates with three divisions hearing cases, comprised of an employers’ representative, a workers’ representative, and a chairperson or deputy chairperson.
Recently, the court has been operating two divisions with two deputy chairs, with an open vacancy for a deputy chair advertised on its website last month.
The Labour Court statement circulated to employment lawyers also advised that a number of part-heard cases would have to be re-heard entirely if the official was not reappointed, and that it was working to identify the affected parties.
The Department of Public Expenditure’s press office referred queries to the Department of Enterprise Trade and Employment. Neither the Labour Court nor the Department of Enterprise answered media queries.
Reacting to the development, barrister Jason Murray, a member of the Employment Bar Association (EBA), said: “It raises serious concerns for all stakeholders concerned in employment rights disputes and industrial relations disputes before the Labour Court.
“The Court is now running at one-third of its capacity. There’s no doubt that in terms of employment rights disputes, when the Supreme Court has determined that our current setup for employment disputes in the Workplace Relations Commission and Labour Court is administering justice, it does raise a question as to whether there is adequate access to justice for litigants,” Mr Murray said.
British telecom company Vodafone is testing the limits of technology by using an AI influencer in its advertisements.
In a video uploaded to the TikTok account of its German subsidiary, a young brunette woman can be seen talking up the company’s connectivity speeds and a 120-euro cashback promotion.
Yet, the woman doesn’t really exist. In reply to a user who picked up on the telltale signs of AI, including the disappearing and reappearing moles on her chin, the company noted that it was experimenting with the technology.
@vodafonedeutschland
Jetzt Internet mit bis zu 1000 Mbit/s im Download für Dein Zuhause. ♬ Originalton – vodafone_de
“…we’re trying out different styles—as AI is now such a big part of everyday life, people are experimenting with it in advertising too,” the company responded in German.
The telecom company has in the past experimented with using AI in advertisements, including in an advertisement “The Rhythm of Life,” published last year. The advertisement started with a birth followed by miscellaneous images of a child playing video games, a person skydiving, and a wedding intertwined with Vodafone branding.
The ad was “100% AI-produced without a single real pixel,” Vodafone’s global senior brand identity and communications manager Amr El Badry told Ad Age in December 2024.
Vodafone did not immediately respond to Fortune’s request for comment.
Vodafone’s most recent TikTok experiment comes as AI influencers become more commonplace. One AI influencer, Lil Miquela, has 2.4 million followers and charges $73,920 per post, according to TheNew York Times.
Lil Miquela has taken selfies with former House Speaker Nancy Pelosi (D-Calif.), has attended the VMAs, and complains on her Instagram about deepfakes of her proliferating online. In the background, the influencer is controlled by a team of people at tech company Dapper Labs.
Influencers are among the most recent jobs being challenged by AI. Recent studies have shown entry-level positions especially vulnerable to automation are being scaled back thanks to AI. A Stanford University study published last month found early-career workers in these fields have experienced a 13% decline in relative employment.
Even some of the people who helped create the technology for this latest AI-driven work revolution have warned about the potential for displacement. Anthropic CEO Dario Amodei earlier this year made waves by predicting AI would eliminate half of all entry-level, white-collar jobs.
The “Godfather of AI” Geoffrey Hinton told the Financial Times “rich people are going to use AI to replace workers,” leading to a huge unemployment spike and record profits. Even Bill Gates, who has been generally optimistic on AI and encouraged Gen Z workers to experiment with it, said being experienced with AI may not prevent job displacement.
Fortune Global Forum returns Oct. 26–27, 2025 in Riyadh. CEOs and global leaders will gather for a dynamic, invitation-only event shaping the future of business. Apply for an invitation.
Hamas says it has received “some ideas” from the US through mediators on how to reach a Gaza ceasefire agreement.
The Palestinian armed group said it was discussing how to develop the ideas, noting that it was ready to release its 48 remaining hostages in Gaza in return for a “clear” declaration ending the war.
A Palestinian official told the BBC the US plan would see the hostages freed in the first 48 hours of a 60-day truce in exchange for Palestinian prisoners in Israeli jails and good-faith negotiations on a permanent ceasefire.
It came after US President Donald Trump gave Hamas what he called a “last warning” to agree a deal. He said Israel had accepted his terms, without giving details.
Israel’s Foreign Minister, Gideon Saar, said it was ready to agree a deal ending the war that would include the release of all the hostages – only 20 of whom are believed to be alive – and the disarmament of Hamas.
Prime Minister Benjamin Netanyahu meanwhile warned the approximately one million Palestinians living in famine-stricken Gaza City to evacuate immediately, as the Israeli military stepped up an offensive to conquer it.
“In the last two days we brought down 50 terrorist high-rises, and this is only the beginning of the ground operation in Gaza City,” he said in a video. “I say to the residents of Gaza City: you have been warned, get out of there.”
Hospitals said Israeli attacks killed at least 40 people across Gaza on Monday, including 25 in Gaza City and elsewhere in the north.
The Israeli military said four soldiers were killed in combat in northern Gaza.
On Sunday evening, Hamas put out a statement saying it had “received through the mediators some ideas from the American side aimed at reaching a ceasefire agreement” and that it welcomed the initiative.
“The movement is in constant contact with the intermediaries to develop these ideas into a comprehensive agreement that meets the needs of our people,” it added.
Hamas said it was ready to immediately negotiate the release of all those who were taken hostage during the group’s attack on Israel on 7 October 2023 in exchange for “a clear declaration to end the war, a full withdrawal from Gaza, and the formation of a committee of Palestinian independents to manage Gaza”.
Earlier in the day, US President Donald Trump had written on Truth Social: “Everyone wants the Hostages HOME. Everyone wants this War to end! The Israelis have accepted my Terms. It is time for Hamas to accept as well.”
“I have warned Hamas about the consequences of not accepting. This is my last warning, there will not be another one!”
A senior Palestinian official familiar with the ceasefire efforts told the BBC that under the US proposal, all of the hostages would be released within the first 48 hours of a 60-day truce in exchange for Palestinian prisoners in Israeli jails, including those serving life sentences and other lengthy terms, and detainees from Gaza.
According to the official, the proposal also includes a personal guarantee from the US president that both sides would hold good-faith negotiations on an end to the war.
During the first two weeks of the truce, the negotiations would cover key issues, including Hamas’s disarmament, the formation of an independent governing body or administrative committee in Gaza, and arrangements for Israeli troop withdrawals, the official said. Humanitarian aid would also flow openly into Gaza.
The framework appeared to be aimed at creating a pathway to a broader settlement while addressing immediate humanitarian and security concerns.
Israeli media quoted political sources as saying that Israel was “seriously considering” the US plan, but also that Hamas was likely to have difficulty accepting it.
On Monday, Israeli Foreign Minister Gideon Saar told a news conference in Budapest: “President Trump said it clearly yesterday, Israel said yes to his proposal. We are ready to accept a full deal that would end the war based on the cabinet’s decision.
“Two things must happen. One, the return of our hostages… [Two], Hamas must lay down its arms.”
Defence Minister Israel Katz at the same time warned Hamas: “Release the hostages and put down your weapons – or Gaza will be destroyed and you will be annihilated.”
The Israeli military has been intensifying its air and ground attacks on Gaza City, and on Monday a fourth high-rise building was destroyed in an air strike in as many days.
Video footage verified by the BBC showed the al-Roya 2 building collapsing after being hit by two projectiles.
Before the strike, the Israeli military ordered dozens of displaced families who had been sheltering inside the building to evacuate along those who had been living in tents pitched in the surrounding area.
The military said Hamas fighters responsible for installing “intelligence gathering means and explosive devices” had been operating near the building and “used it throughout the war to plan and advance terror attacks against [Israeli] forces”.
“We don’t know what to do and where to go. The bombing is insane,” Janine Zoarob, a displaced woman who was living in one of the tents, told Reuters news agency. “I am afraid for my children, I am afraid for myself, and I am afraid for those around me.”
On Saturday, Israel directed displaced people to head to a newly designated “humanitarian area” in southern Gaza for their “safety”. The zone is less than 43 sq km (17 sq miles), which is equivalent to around 12% of the territory.
The military has said there is essential humanitarian infrastructure there. However, the UN has said the tent camps there are already overcrowded and unsafe, and that hospitals are operating several times above capacity.
UN humanitarian chief Tom Fletcher has also warned the window is closing fast to prevent the famine in Gaza City – which was confirmed last month by global food security experts – from spreading to the central city of Deir al-Balah and southern city of Khan Younis by the end of this month.
He called for humanitarian aid to be allowed in unimpeded and at scale, as well as the protection of civilians, a ceasefire and the release of the hostages.
The Israeli military launched a campaign in Gaza in response to the Hamas-led attack on 7 October 2023, in which about 1,200 people were killed and 251 others were taken hostage.
At least 64,522 people have been killed in Israeli attacks in Gaza since then, according to the territory’s Hamas-run health ministry.
The ministry also says 393 people, have so far died during the war as a result of malnutrition and starvation, including six over the past 24 hours.
The concurrent use of durvalumab (Imfinzi) and chemoradiation followed by consolidation durvalumab did not lead to survival benefits compared with chemoradiation alone followed by consolidation durvalumab in patients with unresectable stage III non–small cell lung cancer (NSCLC), according to findings from the phase 3 EA5181 trial (NCT04092283) that were shared at the International Association for the Study of Lung Cancer 2025 World Conference on Lung Cancer.1
In the durvalumab arm, the median overall survival (OS) was 41.5 months (95% CI, 34.4-not reached [NR]) vs 39.4 months (95% CI, 33.4-NR) for patients in the chemoradiation arm (HR, 1.03; 95% CI, 0.80-1.32; P = .83). The median progression-free survival (PFS) was 15.5 months in the durvalumab arm (95% CI, 13.9-22.1) vs 16.4 months (95% CI, 12.0-20.2) in the chemoradiation arm (HR, 1.05; 95% CI, 0.86-1.29; P = .65).
“In patients with unresectable, stage III [NSCLC], the addition of concomitant durvalumab during the course of chemotherapy/radiation did not improve OS, did not improve PFS, did not change the recurrence patterns or ORRs [overall response rates], and did not increase toxicity,” John M. Varlotto, MD, professor and chief of Radiation Oncology at Marshall Health, stated during the presentation.
What Was the Design of the EA5181 Trial?
Patients were randomly assigned 1:1 to receive either platinum doublet durvalumab at 750 mg every 2 weeks plus 3 concurrent rounds of radiotherapy at 60 Gy or platinum doublet chemotherapy with concurrent radiotherapy at 60 Gy. Patients could then transition to consolidation durvalumab at 1500 mg every 4 weeks for 1 year from the end of chemoradiation. This transition could occur within 2 weeks, but may be delayed up to 45 days, depending on whether patients’ toxicities are not grade 2 or less.
Patients were stratified by planned chemotherapy, age, sex, and disease stage. Patients were eligible for treatment if they had unresectable stage IIIA to C NSCLC and had an ECOG performance status of 0 to 1. The primary end point was OS, with secondary end points being PFS, toxicity, ORRs, and recurrence patterns.
A total of 662 patients were randomly assigned to either arm. Varlotto noted the study had an 82% power to detect a 25% reduction in the OS HR rate of 0.01631 to 0.01223, and a 1-sided alpha level of 0.025.
What Baseline Characteristics Were Observed Among Patients in the EA5181 Trial?
The median follow-up was 29.9 months (95% CI, 28.4-33.1). In the durvalumab arm, 335 patients were enrolled, with 305 completing treatment, and 277 moving on to consolidation. In the chemoradiation alone arm, 327 patients were enrolled, 300 completed treatment, and 277 moved on to consolidation.
Across both arms, 60.6% of patients were male, the median age was 67.1 years (range, 37.6-89.4), and 50.6% of patients had stage IIIA disease. Additionally, 48.7% of patients had adenocarcinoma, 53.3% were former smokers, and 82.5% were given carboplatin/paclitaxel.
What Additional Efficacy Findings Were Seen in the EA5181 Trial?
A total of 45.4% of patients experienced disease progression in the durvalumab arm, and 44.0% had it in the chemoradiation arm. Local recurrence was noted in 55.9% vs 49.6% (P = .34), and radiation in-field recurrences were observed in 28.6% vs 28.4% (P = .98).
Prior to consolidation, the ORR was 51.3% in the durvalumab arm and 47.1% in the chemoradiation alone arm (P = .28), while in consolidation, the ORR was 71.5% vs 67.1% (P = .31). In both arms, the median number of consolidative cycles of durvalumab was 10.
What Were the Safety Findings From the EA5181 Trial?
In the durvalumab arm, adverse effects (AEs) of any grade occurred in 99.1% of patients vs 98.7% of those in the chemoradiation alone arm, whereas grade 3/4 AEs were noted in 67.7% of patients in the durvalumab arm vs 62.2% of those in the chemoradiation alone arm. Serious AEs were observed in 3.6% vs 3.5% of patients, respectively, and AEs leading to treatment discontinuation occurred in 19.0% vs 16.5% of patients, respectively.
The most common grade 3 to 5 treatment-related AEs in the durvalumab and chemoradiation alone arms were lymphocyte count decrease (50% vs 45%), white blood cell count decrease (22% vs 27%), esophagitis (21% vs 27%), neutrophil count decrease (16% vs 14%), and pneumonitis (12% vs 5%).
Reference
Varlotto JM, Xie Y, Pennell N, et al. ECOG-ACRIN EA5181: phase 3 trial of concurrent and consolidative durvalumab vs consolidation durvalumab alone for unresectable stage III NSCLC. Presented at the 2025 World Conference on Lung Cancer; Barcelona, Spain; September 6-9, 2025. Abstract PL-3.04.
EXCLUSIVE: Lionsgate has put in motion a sequel to The Last Witch Hunter, to star Vin Diesel in a reprise of his role as Kaulder, the immortal Witch Hunter. The film is being developed along with Diesel’s One Race Films and Lionsgate, with all parties eyeing a fast path to production on the sequel. While a deal has not been finalized, Michael Caine is attached to reprise his role as Dolan in the new film.
The move goes with Lionsgate strategy to grow IP with staying power and sci-fi fantasy spectacle elements that can overperform in the ancillary markets and create long-term library value. The Last Witch Hunter, about the one man who stands between humanity and the most horrible witch covens imaginable, grossed $130 million at the worldwide box office at the time of its initial theatrical release in 2015. Pic has performed consistently in ancillary markets and re-emerged as a streaming hit this year. It ranks among the five most-viewed movies on Netflix. Advancements in technology since then should allow a sequel to be brought on a more efficient budget expenditure. The rest of the elements will be conjured up quickly.
Said Adam Fogelson, chair of Lionsgate’s Motion Picture Group: “The Last Witch Hunter has grown since its theatrical release into a global fan favorite, with audiences continuing to discover and re-watch it across every platform over the past decade. That enduring enthusiasm made clear there is an appetite for more stories set in this world. Vin and I have partnered many times over the years, and he is a true force in our industry. I’m thrilled to be reuniting with him as he returns to this iconic role, and excited by how advancements in filmmaking technology now allow us to economically deliver a sequel on an even more ambitious scale.”
Rian Johnson takes Glenn Close to church in ‘Wake Up, Dead Man: A Knives Out Mystery’ The Washington Post
‘Wake Up Dead Man: A Knives Out Mystery’ Review: Set in a Church Parish, and Pairing Daniel Craig and Josh O’Connor, the Third Entry in the Series May Be the Sharpest Yet Variety
‘Wake Up Dead Man’ Review: Rian Johnson’s Glorious, Goofy Gothic Horror Is the Best ‘Knives Out’ Movie Yet TheWrap
‘Wake Up Dead Man’ Review: Rian Johnson’s Third Knives Out Caps Off One of Film’s Great Trilogies | TIFF 2025 Collider
Wake Up Dead Man Presents Benoit Blanc with a Case Beyond Belief Netflix
